rs137852886
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_000158.4(GBE1):āc.671T>Cā(p.Leu224Pro) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000447 in 1,567,166 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 13/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (ā ā ).
Frequency
Consequence
NM_000158.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GBE1 | NM_000158.4 | c.671T>C | p.Leu224Pro | missense_variant | 5/16 | ENST00000429644.7 | NP_000149.4 | |
GBE1 | XR_007095662.1 | n.799T>C | non_coding_transcript_exon_variant | 5/15 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GBE1 | ENST00000429644.7 | c.671T>C | p.Leu224Pro | missense_variant | 5/16 | 1 | NM_000158.4 | ENSP00000410833 | P1 | |
GBE1 | ENST00000489715.1 | c.548T>C | p.Leu183Pro | missense_variant | 5/16 | 2 | ENSP00000419638 | |||
GBE1 | ENST00000498468.1 | n.199T>C | non_coding_transcript_exon_variant | 2/4 | 3 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152130Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000441 AC: 1AN: 226820Hom.: 0 AF XY: 0.00000810 AC XY: 1AN XY: 123472
GnomAD4 exome AF: 0.00000283 AC: 4AN: 1415036Hom.: 0 Cov.: 24 AF XY: 0.00000284 AC XY: 2AN XY: 703438
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152130Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74300
ClinVar
Submissions by phenotype
Glycogen storage disease, type IV Pathogenic:4
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Nov 19, 2023 | - - |
Pathogenic, no assertion criteria provided | curation | GeneReviews | Apr 02, 2009 | - - |
Likely pathogenic, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Jan 27, 2022 | The p.Leu224Pro variant in GBE1 has been reported in at least 4 individuals with GBE1-related disorders (PMID: 8613547, 25665141, 23034915) and has been identified in 0.01% (1/9498) of Ashkenazi Jewish chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs137852886). Although this variant has been seen in the general population in a heterozygous state, its frequency is not high enough to rule out a pathogenic role. Of the 4 affected individuals, 1 was a compound heterozygote that carried a reported pathogenic variant in trans, and 3 were compound heterozygotes that carried a reported pathogenic variant with unknown phase, which increases the likelihood that the p.Leu224Pro variant is pathogenic (VariationID: 2777; PMID: 8613547, 25665141, 23034915). This variant has also been reported in ClinVar (Variation ID#: 2778) and has been interpreted as likely pathogenic/pathogenic by Counsyl, Invitae, GeneReviews, and OMIM. In vitro functional studies provide some evidence that the p.Leu224Pro variant may slightly impact protein function (PMID: 8613547). However, these types of assays may not accurately represent biological function. Computational prediction tools and conservation analyses suggest that this variant may impact the protein. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic for autosomal recessive GBE1-related disorders. ACMG/AMP Criteria applied: PP3, PS3_supporting, PM3_strong (Richards 2015). - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Feb 13, 2018 | - - |
Adult polyglucosan body neuropathy Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 15, 1996 | - - |
Glycogen storage disease IV, nonprogressive hepatic Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 15, 1996 | - - |
Glycogen storage disease, type IV;C1856301:Glycogen storage disease IV, classic hepatic Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 14, 2023 | This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 224 of the GBE1 protein (p.Leu224Pro). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with glycogen storage disease or polyglucosan body myopathy (PMID: 8613547, 25665141). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 2778). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GBE1 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects GBE1 function (PMID: 8613547). For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at